Four Different Regimens of Farnesyltransferase Inhibitor Tipifarnib in Older, Untreated Acute Myeloid Leukemia Patients: North American Intergroup Phase II Study SWOG S0432

We report on 348 patients ≥ 70 years (median age 78 years) with acute myeloid leukemia (> 50% with secondary AML) randomized to receive either 600 mg or 300 mg of tipifarnib orally twice daily on days 1–21 or days 1–7 and 15–21, repeated every 28 days (4 treatment regimens). Responses were seen i...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Leuk Res
Autori principali: Erba, Harry P., Othus, Megan, Walter, Roland B., Kirschbaum, Mark H., Tallman, Martin S., Larson, Richard A., Slovak, Marilyn L., Kopecky, Kenneth J., Gundacker, Holly M., Appelbaum, Frederick R.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2013
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4247790/
https://ncbi.nlm.nih.gov/pubmed/24411921
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2013.12.001
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi